This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): mAB to TRAIL Receptor 2 - TR2J

Description: HGS-TR2J (TRAIL-R2 mAb) is an agonistic human monoclonal antibody that specifically binds to the TRAIL Receptor-2 protein. TRAIL Receptor 2 often is referred to as a “death receptor” because of its ability to cause apoptosis (programmed cell death) in tumor cells when it is triggered by the natural ligand TRAIL (tumor necrosis factor apoptosis-inducing ligand) . Preclinical studies demonstrate that HGS-TR2J specifically binds TRAIL Receptor 2, induces apoptosis and has anti-tumor activity, both as a single agent and in combination with chemotherapy.

Deal Structure: In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug